Amarin CORP Plcuk 8-K filings

Amarin Corporation plc announced its second quarter 2026 financial results, highlighting global volume growth, reduced operating expenses, and positive cash flow driven by its international commercial strategy.

Amarin Corporation plc announced its first quarter 2026 financial results, showing a 7% increase in total net revenue driven by higher international sales and reiterating its expectation for full-year positive cash flow.

Amarin Corporation plc announced a reduction in its Board size and updated its non-employee director compensation policy, following two directors' decisions not to seek re-election.

Amarin Corporation plc reported significantly narrowed losses and achieved positive cash flow in Q4 2025, driven by strategic initiatives and cost efficiencies.

Amarin Corporation plc announced preliminary unaudited 2025 financial highlights, achieving positive cash flow ahead of schedule and outlining strategic priorities for global expansion.

Amarin Corporation plc reported a 17% increase in total net revenue for Q3 2025, alongside a significant reduction in operating and net losses, driven by U.S. sales and cost discipline.

Amarin Corporation plc announces the appointment of Dr. David Keenan as Executive Vice President and Chief Operating Officer, effective October 17, 2025.

Amarin Corporation plc announced its second quarter 2025 financial results, highlighting a new European partnership with Recordati and a global restructuring expected to yield $70 million in operating expense savings.

Amarin Corporation plc filed an amendment to its 8-K report to provide additional details on new non-employee director Michael Torok's committee assignment and compensation, which includes a cash award due to shareholders' failure to renew pre-emption disapplication for equity grants.

Amarin Corporation plc has entered into an exclusive long-term license and supply agreement with Recordati S.p.A. for VAZKEPA in Europe, alongside a global restructuring expected to yield approximately $70 million in annual cost savings and accelerate its path to positive cash flow.

Amarin Corporation held its Annual General Meeting on May 13, 2025, where all director re-elections and other proposals were approved except for Proposal 12, which concerned the allotment of shares without statutory pre-emption rights.

Amarin Corporation plc announced its first quarter 2025 financial results, highlighting revenue contributions from multiple geographies, efforts to maintain a strong balance sheet, and continued strategic execution to maximize the global value of VASCEPA/VAZKEPA.

Amarin Corporation plc announces it has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market.

Amarin Corporation plc will implement a 1-for-20 reverse split of its American Depositary Shares (ADS) on April 11, 2025, to meet Nasdaq's minimum bid price requirement.

Amarin Corporation plc appoints Michael Torok, Co-Founder and Managing Director of JEC Capital Partners, to its Board of Directors, effective immediately.

Mark DiPaolo will step down from Amarin Corporation's Board of Directors at the conclusion of the 2025 Annual Meeting of Shareholders.

Amarin reports Q4 2024 revenue of $62.3 million and announces a 1-for-20 reverse split of its American Depositary Shares (ADS) to maintain its Nasdaq listing.

Amarin Corporation has appointed Peter Fishman as its new Chief Financial Officer, effective immediately.

Amarin Corporation has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, resulting in a transfer of its listing to the Nasdaq Capital Market.

Amarin reported a mixed third quarter with strong European growth and a solid cash position, but a significant decline in US revenue due to generic competition.

Amarin Corporation's Executive Vice President and CFO, Tom Reilly, has voluntarily resigned, effective October 23, 2024, with Peter Fishman named as interim replacement.

Amarin's Q2 2024 results show a revenue decline due to generic competition, but cost-cutting measures and a new CEO appointment signal a strategic shift.

Amarin Corporation plc has appointed Aaron Berg as President and CEO, effective June 4, 2024, and granted him a performance-based stock option and other compensation.

Amarin Corporation plc announced the resignation of its CEO, Patrick Holt, and the appointment of Aaron Berg as the new President and CEO, effective June 4, 2024, along with a significant change in pharmacy benefit manager coverage for VASCEPA.

Amarin Corporation has received a notice from Nasdaq that its share price has fallen below the required $1.00 minimum, placing it at risk of delisting.

Amarin's Q1 2024 results show strong European growth and a new patent extending exclusivity to 2039, while US revenue declined due to generic competition.

Amarin Corporation plc's shareholders approved a share repurchase program of up to $50 million and re-elected three directors at their Annual General Meeting.

Amarin has successfully extended its European patent protection for VAZKEPA until 2039, reinforcing its market position.

Amarin's Q4 2023 results show a revenue decrease due to generic competition in the US, but the company is initiating a share repurchase program and focusing on cost management.

Amarin Corporation has successfully regained compliance with the NASDAQ's minimum bid price requirement, ensuring its continued listing on the Global Market.